32
Policy Opportunities Portfolio 2018-1 The unit investment trust named above (the “Portfolio”) is included in Invesco Unit Trusts, Series 1841. The Portfolio seeks to provide the potential for above-average capital appreciation by investing in a portfolio of stocks of companies in the S&P 500 ® Index identified as having the highest lobbying intensity using Strategas Securities, LLC’s proprietary methodology. Of course, we cannot guarantee that the Portfolio will achieve its objective. March 1, 2018 You should read this prospectus and retain it for future reference. The Securities and Exchange Commission has not approved or disapproved of the Units or passed upon the adequacy or accuracy of this prospectus. Any contrary representation is a criminal offense.

Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

Embed Size (px)

Citation preview

Page 1: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

Policy Opportunities Portfolio 2018-1

The unit investment trust named above (the “Portfolio”) is included in Invesco Unit Trusts, Series 1841. ThePortfolio seeks to provide the potential for above-average capital appreciation by investing in a portfolio of stocks ofcompanies in the S&P 500® Index identified as having the highest lobbying intensity using Strategas Securities,LLC’s proprietary methodology. Of course, we cannot guarantee that the Portfolio will achieve its objective.

March 1, 2018

You should read this prospectus and retain it for future reference.

The Securities and Exchange Commission has not approved or disapproved of the Unitsor passed upon the adequacy or accuracy of this prospectus.

Any contrary representation is a criminal offense.

INVESCO

Page 2: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

Investment Objective. The Portfolio seeks toprovide the potential for above-average capitalappreciation.

Principal Investment Strategy. The Portfolioseeks to achieve its objective by investing in aportfolio of stocks of companies in the S&P 500®

Index with the highest “lobbying intensity” identified byusing Strategas Securities, LLC’s (the “PortfolioConsultant” or “Strategas”) proprietary methodology.Invesco Capital Markets, Inc., is the Sponsor of thePortfolio.

Lobbying is the attempt to influence the decisionsand actions of policymakers, regulators, and othergovernment officials. The methodology employs aquantitative approach to identify companies in theS&P 500® Index with the highest dollar amounts spenton lobbying activit ies relat ive to the individualcompany’s size, referred to as the company’slobbying intensity. While a variety of individuals orgroups can engage in lobbying activities, the PortfolioConsultant looks primarily at lobbying dollars spent bycompanies for purposes of choosing securities for theportfol io. Companies often engage in lobbyingactivities to position themselves before a shift in publicpolicy or to fend off challenges to their businessmodels, both of which can impact the earnings ofthese companies.

Of course, we cannot guarantee that your Portfoliowill achieve its objective. The value of your Units mayfall below the price you paid for the Units. You shouldread the “Risk Factors” section before you invest.

The Portfolio is designed as part of a long-terminvestment strategy. The Sponsor may offer asubsequent series of the portfolio when the currentPortfolio terminates. As a result, you may achievemore consistent overall results by following thestrategy through reinvestment of your proceeds overseveral years if subsequent series are available.Repeatedly rol l ing over an investment in a unitinvestment trust may differ from long-term investmentsin other investment products when considering the

sales charges, fees, expenses and tax consequencesattributable to a Unitholder. For more information see“Rights of Unitholders--Rollover”.

Principal Risks. As with all investments, you canlose money by investing in this Portfolio. The Portfolioalso might not perform as well as you expect. This canhappen for reasons such as these:

• Security prices will fluctuate. The value ofyour investment may fall over time.

• An issuer may be unwilling or unable todeclare dividends in the future, or mayreduce the level of dividends declared.This may result in a reduction in the value ofyour Units.

• The financial condition of an issuer mayworsen or its credit ratings may drop,resulting in a reduction in the value ofyour Units. This may occur at any point intime, including during the initial offering period.

• You could experience dilution of yourinvestment if the size of the Portfolio isincreased as Units are sold. There is noassurance that your investment will maintain itsproportionate share in the Portfolio’s profits andlosses.

• The Portfolio Consultant's selectionstrategy may not be successful. Thecompanies identified might not necessarilyhave the highest levels of lobbying intensity,and further, the stocks of such companiesmay not perform as anticipated over the life ofthe Portfolio. The Portfolio may not achieve itsobjectives if this happens.

• The Portfolio is concentrated insecurities issued by companies in theindustrials sector. Negative developmentsin this sector will affect the value of yourinvestment more than would be the case in amore diversified investment.

2

Policy Opportunities Portfolio

Page 3: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

• We do not actively manage the Portfolio.Except in limited circumstances, the Portfoliowill hold, and may continue to buy, shares ofthe same securities even if their market valuedeclines.

3

Page 4: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

4

Fee Table

The amounts below are estimates of the direct and indirectexpenses that you may incur based on a $10 Public Offering Price perUnit. Actual expenses may vary.

As a % of Public Amount Offering Per 100Sales Charge Price Units _________ _________

Initial sales charge 0.000% $ 0.000Deferred sales charge 1.350 13.500Creation and development fee 0.500 5.000 ______ ______Maximum sales charge 1.850% $18.500 ______ ______ ______ ______

As a % Amount of Net Per 100 Assets Units _________ _________

Estimated Organization Costs 0.512% $5.000 ______ ______ ______ ______

Estimated Annual Expenses Trustee’s fee and operating expenses 0.203% $1.983Supervisory, bookkeeping

and administrative fees 0.056 0.550 ______ ______

Total 0.259% $2.533* ______ ______ ______ ______

Example

This example helps you compare the cost of the Portfolio with otherunit trusts and mutual funds. In the example we assume that theexpenses do not change and that the Portfolio’s annual return is 5%. Youractual returns and expenses will vary. This example also assumes that youcontinue to follow the Portfolio strategy and roll your investment, includingall distributions, into a new trust each year subject to a sales charge of1.85%. Based on these assumptions, you would pay the followingexpenses for every $10,000 you invest in the Portfolio:

1 year $ 260 3 years 799 5 years 1,362 10 years 2,886

* The estimated annual expenses are based upon the estimated trust sizefor the Portfolio determined as of the initial date of deposit. Becausecertain of the operating expenses are fixed amounts, if the Portfolio doesnot reach the estimated size, or if the value of the Portfolio or number ofoutstanding units decline over the life of the trust, or if the actual amountof the operating expenses exceeds the estimated amounts, the actualamount of the operating expenses per 100 units would exceed theestimated amounts. In some cases, the actual amount of operatingexpenses may substantially differ from the amounts reflected above.

The maximum sales charge is 1.85% of the Public Offering Priceper Unit. There is no initial sales charge at a Public Offering Price of $10or less. If the Public Offering Price exceeds $10 per Unit, the initial salescharge is the difference between the total sales charge (maximum of1.85% of the Public Offering Price) and the sum of the remainingdeferred sales charge and the creation and development fee. Thedeferred sales charge is fixed at $0.135 per Unit and accrues daily fromJune 10, 2018 through November 9, 2018. Your Portfolio pays aproportionate amount of this charge on the 10th day of each monthbeginning in the accrual period until paid in full. The combination of theinitial and deferred sales charges comprises the “transactional salescharge”. The creation and development fee is fixed at $0.05 per Unitand is paid at the earlier of the end of the initial offering period(anticipated to be three months) or six months following the Initial Dateof Deposit. For more detail, see “Public Offering Price -- General.”

Essential Information

Unit Price at Initial Date of Deposit $10.0000

Initial Date of Deposit March 1, 2018

Mandatory Termination Date June 3, 2019

Estimated Net Annual Income1 $0.12563 per Unit

Estimated Initial Distribution1 $0.02 per Unit

Record Date 10th day of each June,

September and December,

commencing June 10, 2018

Distribution Date 25th day of each June,

September and December,

commencing June 25, 2018

CUSIP Numbers Cash – 46140Y620

Reinvest – 46140Y638

Wrap Fee Cash – 46140Y646

Wrap Fee Reinvest – 46140Y653

1 As of close of business day prior to Initial Date of Deposit. The actualdistributions you receive will vary from the estimated amount due tochanges in the Portfolio’s fees and expenses, in actual income receivedby the Portfolio, currency fluctuations and with changes in the Portfoliosuch as the acquisition or liquidation of securities. See “Rights ofUnitholders--Estimated Distributions.”

Page 5: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

5

Policy Opportunities Portfolio 2018-1

Portfolio______________________________________________________________________________________________________________ Current Cost ofNumber Market Value Dividend Securities toof Shares Name of Issuer (1) per Share (2) Yield (3) Portfolio (2) __________ ___________________________________ _______________ ___________ _____________

Consumer Discretionary - 16.07% 41 Best Buy Company, Inc. $ 72.440 1.88% $ 2,970.04 56 CBS Corporation - CL B 52.970 1.36 2,966.32 93 Gap, Inc. 31.580 2.91 2,936.94 100 Goodyear Tire & Rubber Company 28.940 1.94 2,894.00 116 H&R Block, Inc. 25.330 3.79 2,938.28 73 TripAdvisor, Inc. 40.080 0.00 2,925.84 89 Viacom Inc. - CL B 33.340 2.40 2,967.26 36 Yum! Brands, Inc. 81.380 1.77 2,929.68 Consumer Staples - 5.96% 46 Altria Group, Inc. 62.950 4.19 2,895.70 42 Brown-Forman Corporation - CL B 69.790 1.13 2,931.18 28 Philip Morris International, Inc. 103.550 4.13 2,899.40 Energy - 1.97% 44 Occidental Petroleum Corporation 65.600 4.70 2,886.40 Financials - 3.95% 26 Cboe Global Markets, Inc. 112.010 0.96 2,912.26 15 S&P Global, Inc. 191.800 1.04 2,877.00 Health Care - 14.12% 16 Amgen, Inc. 183.770 2.87 2,940.32 29 Centene Corporation 101.420 0.00 2,941.18 41 DaVita, Inc. 72.020 0.00 2,952.82 22 Edwards Lifesciences Corporation 133.670 0.00 2,940.74 38 Eli Lilly and Company 77.020 2.92 2,926.76 25 Varian Medical Systems, Inc. 119.340 0.00 2,983.50 18 Vertex Pharmaceuticals, Inc. 166.030 0.00 2,988.54 Industrials - 31.86% 46 A.O. Smith Corporation 64.190 1.12 2,952.74 55 American Airlines Group, Inc. 54.250 0.74 2,983.75 8 Boeing Company 362.210 1.89 2,897.68 17 Cummins, Inc. 168.170 2.57 2,858.89 26 Equifax, Inc. 113.000 1.38 2,938.00 12 FedEx Corporation 246.410 0.81 2,956.92 51 Fluor Corporation 56.900 1.48 2,901.90 13 General Dynamics Corporation 222.450 1.51 2,891.85 19 Harris Corporation 156.150 1.46 2,966.85 11 Huntington Ingalls Industries, Inc. 262.010 1.10 2,882.11 14 L3 Technologies, Inc. 207.550 1.54 2,905.70 8 Lockheed Martin Corporation 352.440 2.27 2,819.52 8 Northrop Grumman Corporation 350.040 1.26 2,800.32 14 Raytheon Company 217.510 1.47 3,045.14 49 Textron, Inc. 59.850 0.13 2,932.65 28 United Parcel Service, Inc. - CL B 104.410 3.49 2,923.48

Page 6: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

6

Policy Opportunities Portfolio 2018-1

Portfolio (continued)______________________________________________________________________________________________________________ Current Cost ofNumber Market Value Dividend Securities toof Shares Name of Issuer (1) per Share (2) Yield (3) Portfolio (2) __________ ___________________________________ _______________ ___________ _____________

Information Technology - 20.08%+ 18 Accenture plc - CL A $ 161.010 1.65% $ 2,898.18 242 Advanced Micro Devices, Inc. 12.110 0.00 2,930.62 16 Facebook, Inc. - CL A 178.320 0.00 2,853.12 60 FLIR Systems, Inc. 49.100 1.30 2,946.00 18 Intuit, Inc. 166.860 0.93 3,003.48 17 Mastercard, Inc. - CL A 175.760 0.57 2,987.92 28 Motorola Solutions, Inc. 106.150 1.96 2,972.20 45 QUALCOMM, Inc. 65.000 3.51 2,925.00 34 Total System Services, Inc. 87.950 0.59 2,990.30 25 VeriSign, Inc. 116.020 0.00 2,900.50 Materials - 3.98% 29 Eastman Chemical Company 101.080 2.22 2,931.32 37 FMC Corporation 78.480 0.84 2,903.76 Real Estate - 2.01% 84 Weyerhaeuser Company 35.030 3.65 2,942.52__________ ____________ 2,026 $ 146,446.58__________ ______________________ ____________

See “Notes to Portfolio”.

Page 7: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

7

Notes to Portfolio

(1) The Securities are initially represented by “regular way” contracts for the performance of which an irrevocable letter ofcredit has been deposited with the Trustee. Contracts to acquire Securities were entered into on February 28, 2018 andhave a settlement date of March 2, 2018 (see “The Portfolio”).

(2) The value of each Security is determined on the bases set forth under “Public Offering--Unit Price” as of the close of theNew York Stock Exchange on the business day before the Initial Date of Deposit. In accordance with FASB AccountingStandards Codification (“ASC”), ASC 820, Fair Value Measurements and Disclosures, the Portfolio’s investments areclassified as Level 1, which refers to security prices determined using quoted prices in active markets for identicalsecurities. Other information regarding the Securities, as of the Initial Date of Deposit, is as follows:

Profit Cost to (Loss) To Sponsor Sponsor ______________ _____________

$ 146,497 $ (50)

“+” indicates that the stock was issued by a foreign company.

(3) Current Dividend Yield for each Security is based on the estimated annual dividends per share and the Security’s valueas of the most recent close of trading on the New York Stock Exchange on the business day before the Initial Date ofDeposit. Generally, estimated annual dividends per share are calculated by annualizing the most recently declaredregular dividends or by adding the most recent regular interim and final dividends declared and reflect any foreignwithholding taxes. In certain cases, this calculation may consider several recently declared dividends in order for theCurrent Dividend Yield to be more reflective of recent historical dividend rates.

Page 8: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

8

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Sponsor and Unitholders of Invesco Unit Trusts, Series 1841:

Opinion on the Financial Statements

We have audited the accompanying statement of condition (including the related portfolio schedule) of PolicyOpportunities Portfolio 2018-1 (included in Invesco Unit Trusts, Series 1841 (the “Trust”)) as of March 1, 2018,and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statementspresent fairly, in all material respects, the financial position of the Trust as of March 1, 2018, in conformity withaccounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of Invesco Capital Markets, Inc., Sponsor. Ourresponsibility is to express an opinion on the Trust’s financial statements based on our audit. We are a publicaccounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)and are required to be independent with respect to the Trust in accordance with the U.S. federal securitieslaws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require thatwe plan and perform the audit to obtain reasonable assurance about whether the financial statements arefree of material misstatement, whether due to error or fraud. The Trust is not required to have, nor were weengaged to perform, an audit of its internal control over financial reporting. As part of our audit we arerequired to obtain an understanding of internal control over financial reporting but not for the purpose ofexpressing an opinion on the effectiveness of the Trust’s internal control over financial reporting. Accordingly,we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financialstatements, whether due to error or fraud, and performing procedures that respond to those risks. Suchprocedures included examining, on a test basis, evidence regarding the amounts and disclosures in thefinancial statements. Our audit also included evaluating the accounting principles used and significantestimates made by the Sponsor, as well as evaluating the overall presentation of the financial statements. Ourprocedures included confirmation of cash or an irrevocable letter of credit deposited for the purchase ofsecurities as shown in the statement of condition as of March 1, 2018 by correspondence with The Bank ofNew York Mellon, Trustee. We believe that our audit provides a reasonable basis for our opinion.

/s/ GRANT THORNTON LLP

We have served as the auditor of one or more of the unit investment trusts, sponsored by Invesco CapitalMarkets, Inc. and its predecessors, since 1976.

New York, New YorkMarch 1, 2018

Page 9: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

9

STATEMENT OF CONDITIONAs of March 1, 2018

INVESTMENT IN SECURITIESContracts to purchase Securities (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 146,447 ___________ Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 146,447 ___________ ___________

LIABILITIES AND INTEREST OF UNITHOLDERSLiabilities-- Organization costs (2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 733 Deferred sales charge liability (3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,977 Creation and development fee liability (4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732Interest of Unitholders-- Cost to investors (5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146,447Less: deferred sales charge, creation and development fee and organization costs (2)(4)(5)(6) . . . . . . . . . . . . . . . . 3,442 ___________ Net interest to Unitholders (5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143,005 ___________ Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 146,447 ___________ ___________Units outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,645 ___________ ___________Net asset value per Unit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 9.765 ___________ ___________

(1) The value of the Securities is determined by the Trustee on the bases set forth under “Public Offering--Unit Price”. The contracts to purchaseSecurities are collateralized by an irrevocable letter of credit which has been deposited with the Trustee.

(2) A portion of the Public Offering Price represents an amount sufficient to pay for all or a portion of the costs incurred in establishing thePortfolio. The amount of these costs are set forth in the “Fee Table”. A distribution will be made as of the earlier of the close of the initial offeringperiod (approximately three months) or six months following the Initial Date of Deposit to an account maintained by the Trustee from which theorganization expense obligation of the investors will be satisfied. To the extent that actual organization costs of the Portfolio are greater thanthe estimated amount, only the estimated organization costs added to the Public Offering Price will be reimbursed to the Sponsor anddeducted from the assets of the Portfolio.

(3) Represents the amount of mandatory distributions from the Portfolio on the bases set forth under “Public Offering”.(4) The creation and development fee is payable by the Portfolio on behalf of Unitholders out of the assets of the Portfolio as of the close of the

initial offering period. If Units are redeemed prior to the close of the initial public offering period, the fee will not be deducted from the proceeds.(5) The aggregate public offering price and the aggregate sales charge are computed on the bases set forth under “Public Offering”.(6) Assumes the maximum sales charge.

Page 10: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-1

THE PORTFOLIO

The Portfolio was created under the laws of the Stateof New York pursuant to a Trust Indenture and TrustAgreement (the “Trust Agreement”), dated the date ofthis prospectus (the “Initial Date of Deposit”), amongInvesco Capital Markets, Inc., as Sponsor, InvescoInvestment Advisers LLC, as Supervisor, and The Bankof New York Mellon, as Trustee.

The Portfolio offers investors the opportunity topurchase Units representing proportionate interests in aportfolio of securities. The Portfolio may be an appropriatemedium for investors who desire to participate in aportfolio of securities with greater diversification than theymight be able to acquire individually.

On the Initial Date of Deposit, the Sponsor depositeddelivery statements relating to contracts for thepurchase of the Securities and an irrevocable letter ofcredit in the amount required for these purchases withthe Trustee. In exchange for these contracts the Trusteedelivered to the Sponsor documentation evidencing theownership of Units of the Portfolio. Unless otherwiseterminated as provided in the Trust Agreement, thePortfolio will terminate on the Mandatory TerminationDate and any remaining Securities will be liquidated ordistributed to the Trustee within a reasonable time. Asused in this prospectus the term “Securities” means thesecurities (including contracts to purchase thesesecurities) listed in the “Portfolio” and any additionalsecurities deposited into the Portfolio.

Additional Units of the Portfolio may be issued at anytime by depositing in the Portfolio (i) additional Securities,(ii) contracts to purchase Securities together with cash orirrevocable letters of credit or (iii) cash (or a letter of creditor the equivalent) with instructions to purchase additionalSecurities. As additional Units are issued by the Portfolio,the aggregate value of the Securities will be increasedand the fractional undivided interest represented by eachUnit may be decreased. The Sponsor may continue tomake additional deposits into the Portfolio following theInitial Date of Deposit provided that the additionaldeposits will be in amounts which will maintain, as nearlyas practicable, the same percentage relationship amongthe number of shares of each Security in the Portfolio

that existed immediately prior to the subsequent deposit.Investors may experience a dilution of their investmentsand a reduction in their anticipated income because offluctuations in the prices of the Securities between thetime of the deposit and the purchase of the Securitiesand because the Portfolio will pay the associatedbrokerage or acquisition fees. In addition, during the initialoffering of Units it may not be possible to buy a particularSecurity due to regulatory or trading restrictions, orcorporate actions. While such limitations are in effect,additional Units would be created by purchasing each ofthe Securities in your Portfolio that are not subject tothose limitations. This would also result in the dilution ofthe investment in any such Security not purchased andpotential variances in anticipated income. Purchases andsales of Securities by your Portfolio may impact the valueof the Securities. This may especially be the case duringthe initial offering of Units, upon Portfolio termination andin the course of satisfying large Unit redemptions.

Each Unit of your Portfolio initially offered representsan undivided interest in the Portfolio. At the close of theNew York Stock Exchange on the Init ial Date ofDeposit, the number of Units may be adjusted so thatthe Public Offering Price per Unit equals $10. Thenumber of Units, fractional interest of each Unit in yourPortfolio and the estimated distributions per Unit willincrease or decrease to the extent of any adjustment.To the extent that any Units are redeemed to theTrustee or additional Units are issued as a result ofadditional Securities being deposited by the Sponsor,the fractional undivided interest in your Portfoliorepresented by each unredeemed Unit will increase ordecrease accordingly, although the actual interest inyour Portfolio will remain unchanged. Units will remainoutstanding until redeemed upon tender to the Trusteeby Unitholders, which may include the Sponsor, or untilthe termination of the Trust Agreement.

The Portfolio consists of (a) the Securities (includingcontracts for the purchase thereof) l isted under“Portfolio” as may continue to be held from time to timein the Portfolio, (b) any additional Securities acquiredand held by the Portfolio pursuant to the provisions ofthe Trust Agreement and (c) any cash held in the relatedIncome and Capital Accounts. Neither the Sponsor nor

Page 11: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-2

the Trustee shall be liable in any way for any contractfailure in any of the Securities.

OBJECTIVE AND SECURITIES SELECTION

The objective of the Portfolio is described on page 2.There is no assurance that the Portfolio will achieve itsobjective.

The Portfolio Consultant is not an affiliate of theSponsor. The Portfolio Consultant may use the list ofSecurities in its independent capacity as an investmentadviser and distributes this information to variousindividuals and entities. The Portfolio Consultant mayrecommend or effect transactions in the Securities.This may have an adverse effect on the prices of theSecurities. This also may have an impact on the priceyour Portfolio pays for the Securities and the pricereceived upon Unit redemptions or Portfol iotermination. The Portfolio Consultant may act as agentor principal in connection with the purchase and sale ofsecurities, including the Securities, and may act as amarket maker in the Securit ies. The Portfol ioConsultant may also issue reports and makesrecommendations on the Securities. The PortfolioConsultant’s research department may receivecompensation based on commissions generated byresearch and/or sales of Units.

Neither the Portfolio Consultant nor the Sponsormanages the Portfolio. You should note that theSponsor applied the selection criteria to the Securitiesfor inclusion in the Portfolio prior to the Initial Date ofDeposit. After the initial selection date, the Securitiesmay no longer meet the selection criteria. Should aSecurity no longer meet the selection criteria, we willgenerally not remove the Security from the Portfolio. Inoffering the Units to the public, neither the Sponsor norany broker-dealers are recommending any of theindividual Securities but rather the entire pool ofSecurities in the Portfolio, taken as a whole, which arerepresented by the Units.

RISK FACTORS

All investments involve risk. This section describesthe main r isks that can impact the value of the

securities in your Portfolio. You should understandthese risks before you invest. If the value of thesecurities falls, the value of your Units will also fall. Wecannot guarantee that your Portfolio will achieve itsobjective or that your investment return will be positiveover any period.

Market Risk. Market risk is the risk that the value ofthe securities in your Portfolio will fluctuate. This couldcause the value of your Units to fall below your originalpurchase price. Market value fluctuates in response tovarious factors. These can include changes in interestrates, inflation, the financial condition of a security’s issuer,perceptions of the issuer, or ratings on a security of theissuer. Even though your Portfolio is supervised, youshould remember that we do not manage your Portfolio.Your Portfolio will not sell a security solely because themarket value falls as is possible in a managed fund.

Dividend Payment Risk. Dividend payment risk isthe risk that an issuer of a security is unwilling or unableto pay dividends on a security. Stocks representownership interests in the issuers and are notobligations of the issuers. Common stockholders havea right to receive dividends only after the company hasprovided for payment of its creditors, bondholders andpreferred stockholders. Common stocks do not assuredividend payments. Dividends are paid only whendeclared by an issuer’s board of directors and theamount of any dividend may vary over time. If dividendsreceived by your Portfolio are insufficient to coverexpenses, redemptions or other Portfolio costs, it maybe necessary for your Portfolio to sell Securities tocover such expenses, redemptions or other costs. Anysuch sales may result in capital gains or losses to you.See “Taxation”.

Strategy Risk. The Portfol io Consultant'sinvestment premise and portfolio selection strategy maynot be successful in identifying securities that appreciatein value. The Portfolio may not achieve its objectives ifthis happens.

Industry Risks. Your Portfolio may invest significantlyin certain industries. Any negative impact on the relatedindustry will have a greater impact on the value of Unitsthan on a portfolio diversified over several industries. You

Page 12: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-3

should understand the risks of these industries beforeyou invest.

Consumer Discretionary and Consumer StaplesIssuers. Your Portfolio invests significantly in companiesthat manufacture or sell various consumer products.General risks of these companies include the overallstate of the economy, intense competit ion andconsumer spending trends. A decline in the economywhich results in a reduction of consumers’ disposableincome can negatively impact spending habits. Globalfactors including political developments, imposition ofimport controls, fluctuations in oil prices, and changesin exchange rates may adversely affect issuers ofconsumer products and services.

Competitiveness in the retail industry may requirelarge capital outlays for the installation of automatedcheckout equipment to control inventory, track the saleof items and gauge the success of sales campaigns.Retailers who sell their products over the Internet havethe potential to access more consumers, but mayrequire sophisticated technology to remain competitive.Changes in demographics and consumer tastes canalso affect the demand for, and the success of,consumer products and services in the marketplace.Consumer products and services companies may besubject to government regulation affecting their productsand operations which may negatively impactperformance. Tobacco companies may be adverselyaffected by new laws, regulations and litigation.

Industrials Issuers. Your Portfolio invests significantly inindustrials companies. General risks of industrialscompanies include the general state of the economy,intense competition, imposition of import controls, volatilityin commodity prices, currency exchange rate fluctuation,consolidation, labor relations, domestic and internationalpolitics, excess capacity and consumer spending trends.Companies in the industrials sector may be adverselyaffected by liability for environmental damage and productliability claims. Capital goods companies may also besignificantly affected by overall capital spending andleverage levels, economic cycles, technical obsolescence,delays in modernization, limitations on supply of keymaterials, depletion of resources, government regulations,government contracts and e-commerce initiatives.

Industrials companies may also be affected by factorsmore specific to their individual industries. Industrialmachinery manufacturers may be subject to declines incommercial and consumer demand and the need formodernization. Aerospace and defense companies maybe influenced by decreased demand for new equipment,aircraft order cancellations, disputes over or ability toobtain or retain government contracts, changes ingovernment budget priorities, changes in aircraft-leasingcontracts and cutbacks in profitable business travel. Thenumber of housing starts, levels of public and non-residential construction including weakening demand fornew office and retail space, and overall constructionspending may adversely affect construction materialsand equipment manufacturers. Stocks of transportationcompanies are cyclical and can be significantly affectedby economic changes, fuel prices and insurance costs.Transportation companies in certain countries may alsobe subject to significant government regulation andoversight, which may negatively impact their businesses.

Technology Issuers. Your Portfolio invests significantlyin the technology sector which includes informationtechnology companies. These companies includecompanies that are involved in computer and businessservices, enterprise software/technical software, Internetand computer software, Internet-related services,networking and telecommunications equipment,telecommunications services, electronics products, serverhardware, computer hardware and peripherals,semiconductor capital equipment and semiconductors.These companies face risks related to rapidly changingtechnology, rapid product obsolescence, cyclical marketpatterns, evolving industry standards and frequent newproduct introductions. An unexpected change intechnology can have a significant negative impact on acompany. The failure of a company to introduce newproducts or technologies or keep pace with rapidlychanging technology, can have a negative impact on thecompany’s results. Information technology stocks tend toexperience substantial price volatility and speculativetrading. Announcements about new products,technologies, operating results or marketing alliances cancause stock prices to fluctuate dramatically. At times,however, extreme price and volume fluctuations are

Page 13: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-4

unrelated to the operating performance of a company.This can impact your ability to redeem your Units at aprice equal to or greater than what you paid.

Legislation/Litigation. From time to time, variouslegislative initiatives are proposed in the United Statesand abroad which may have a negative impact oncertain of the companies represented in the Portfolio oron the tax treatment of your Portfolio or of yourinvestment in the Portfolio. In addition, l it igationregarding any of the issuers of the Securities or of theindustries represented by these issuers may negativelyimpact the share prices of these Securities. No one canpredict what impact any pending or threatened litigationwill have on the share prices of the Securities.

Liquidity Risk. Liquidity risk is the risk that thevalue of a security will fall if trading in the security islimited or absent. The market for certain investmentsmay become less liquid or illiquid due to adversechanges in the conditions of a particular issuer or dueto adverse market or economic conditions. In theabsence of a liquid trading market for a particularsecurity, the price at which such security may be soldto meet redemptions, as well as the value of the Unitsof your Portfolio, may be adversely affected. No onecan guarantee that a liquid trading market will exist forany security.

No FDIC Guarantee. An investment in your Portfoliois not a deposit of any bank and is not insured orguaranteed by the Federal Deposit InsuranceCorporation or any other government agency.

PUBLIC OFFERING

General. Units are offered at the Public OfferingPrice which consists of the net asset value per Unit plusorganization costs plus the sales charge. The net assetvalue per Unit is the value of the securities, cash andother assets in your Portfolio reduced by the liabilities ofthe Portfolio divided by the total Units outstanding. Themaximum sales charge equals 1.85% of the PublicOffering Price per Unit (1.885% of the aggregateoffering price of the Securities) at the time of purchase.

The initial sales charge is the difference between thetotal sales charge amount (maximum of 1.85% of the

Public Offering Price per Unit) and the sum of theremaining fixed dollar deferred sales charge and thefixed dollar creation and development fee (initially $0.185per Unit). Depending on the Public Offering Price perUnit, you pay the initial sales charge at the time you buyUnits. The deferred sales charge is fixed at $0.135 perUnit. Your Portfolio pays the deferred sales charge ininstallments as described in the “Fee Table.” If anydeferred sales charge payment date is not a businessday, we will charge the payment on the next businessday. If you purchase Units after the initial deferred salescharge payment, you will only pay that portion of thepayments not yet collected. If you redeem or sell yourUnits prior to collection of the total deferred salescharge, you will pay any remaining deferred sales chargeupon redemption or sale of your Units. The initial anddeferred sales charges are referred to as the“transactional sales charge.” The transactional salescharge does not include the creation and developmentfee which compensates the Sponsor for creating anddeveloping your Portfolio and is described under“Expenses.” The creation and development fee is fixedat $0.05 per Unit. Your Portfolio pays the creation anddevelopment fee as of the close of the initial offeringperiod as described in the “Fee Table.” If you redeem orsell your Units prior to collection of the creation anddevelopment fee, you will not pay the creation anddevelopment fee upon redemption or sale of your Units.After the initial offering period the maximum sales chargewill be reduced by 0.50%, reflecting the previouscollection of the creation and development fee. Becausethe deferred sales charge and creation and developmentfee are fixed dollar amounts per Unit, the actual chargeswill exceed the percentages shown in the “Fee Table” ifthe Public Offering Price per Unit falls below $10 and willbe less than the percentages shown in the “Fee Table” ifthe Public Offering Price per Unit exceeds $10. In noevent will the maximum total sales charge exceed1.85% of the Public Offering Price per Unit.

The “Fee Table” shows the sales charge calculation ata $10 Public Offering Price per Unit. At a $10 PublicOffering Price, there is no initial sales charge during theinitial offering period. If the Public Offering Price exceeds$10 per Unit, you will pay an initial sales charge equal to

Page 14: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-5

the difference between the total sales charge and the sumof the remaining deferred sales charge and the creationand development fee. For example, if the Public OfferingPrice per Unit rose to $14, the maximum sales chargewould be $0.259 (1.85% of the Public Offering Price perUnit), consisting of an initial sales charge of $0.074, adeferred sales charge of $0.135 and the creation anddevelopment fee of $0.050. Since the deferred salescharge and creation and development fee are fixed dollaramounts per Unit, your Portfolio must charge theseamounts per Unit regardless of any decrease in net assetvalue. However, if the Public Offering Price per Unit falls tothe extent that the maximum sales charge percentageresults in a dollar amount that is less than the combinedfixed dollar amounts of the deferred sales charge andcreation and development fee, your initial sales charge willbe a credit equal to the amount by which these fixeddollar charges exceed your sales charge at the time youbuy Units. In such a situation, the value of securities perUnit would exceed the Public Offering Price per Unit bythe amount of the initial sales charge credit and the valueof those securities will fluctuate, which could result in abenefit or detriment to Unitholders that purchase Units atthat price. The initial sales charge credit is paid by theSponsor and is not paid by the Portfolio. If the PublicOffering Price per Unit fell to $6, the maximum salescharge would be $0.111 (1.85% of the Public OfferingPrice per Unit), which consists of an initial sales charge(credit) of -$0.074, a deferred sales charge of $0.135 anda creation and development fee of $0.050.

The actual sales charge that may be paid by aninvestor may differ slightly from the sales chargesshown herein due to rounding that occurs in thecalculation of the Public Offering Price and in thenumber of Units purchased.

The minimum purchase is 100 Units (25 Units forretirement accounts) but may vary by selling firm.Certain broker-dealers or selling firms may charge anorder handling fee for processing Unit purchases.

Reducing Your Sales Charge. The Sponsoroffers ways for you to reduce the sales charge that youpay. It is your financial professional’s responsibility toalert the Sponsor of any discount when you purchaseUnits. Before you purchase Units you must also inform

your financial professional of your qualification for anydiscount to be eligible for a reduced sales charge. Sincethe deferred sales charges and creation anddevelopment fee are fixed dollar amounts per Unit, yourPortfol io must charge these amounts per Unitregardless of any discounts. However, if you are eligibleto receive a discount such that your total sales chargeis less than the fixed dollar amounts of the deferredsales charges and creation and development fee, youwill receive a credit equal to the difference between yourtotal sales charge and these fixed dollar charges at thetime you buy Units.

Fee Accounts. Investors may purchase Units throughregistered investment advisers, certified financialplanners and registered broker-dealers who in eachcase either charge periodic fees for brokerage services,f inancial planning, investment advisory or assetmanagement services, or provide such services inconnection with the establishment of an investmentaccount for which a comprehensive “wrap fee” charge(“Wrap Fee”) is imposed (“Fee Accounts”). If Units of thePortfolio are purchased for a Fee Account and thePortfolio is subject to a Wrap Fee (i.e., the Portfolio is“Wrap Fee Eligible”), then the purchase will not besubject to the transactional sales charge but will besubject to the creation and development fee of $0.05per Unit that is retained by the Sponsor. Please refer tothe section called “Fee Accounts” for additionalinformation on these purchases. The Sponsor reservesthe right to limit or deny purchases of Units described inthis paragraph by investors or selling firms whosefrequent trading activity is determined to be detrimentalto the Portfolio. Wrap Fee Eligible Units are not eligiblefor any sales charge discounts in addition to that whichis described in this paragraph and under the “FeeAccounts” section found below.

Employees. Employees, officers and directors(including their spouses (or the equivalent if recognizedunder local law) and children or step-children under 21living in the same household, parents or step-parentsand trustees, custodians or fiduciaries for the benefit ofsuch persons) of Invesco Capital Markets, Inc. and itsaffiliates, and dealers and their affiliates may purchaseUnits at the Public Offering Price less the applicable

Page 15: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-6

dealer concession. All employee discounts are subjectto the pol icies of the related sel l ing f irm. Onlyemployees, officers and directors of companies thatallow their employees to participate in this employeediscount program are eligible for the discounts.

Distribution Reinvestments. We do not charge anysales charge when you reinvest distributions from yourPortfolio into additional Units of your Portfolio. Since thedeferred sales charges and creation and developmentfee are fixed dollar amounts per unit, your Portfolio mustcharge these amounts per unit regardless of thisdiscount. If you elect to reinvest distributions, theSponsor will credit you with additional Units with a dollarvalue sufficient to cover the amount of any remainingdeferred sales charge and creation and developmentfee that will be collected on such Units at the time ofreinvestment. The dollar value of these Units willfluctuate over time.

Unit Price. The Public Offering Price of Units willvary from the amounts stated under “EssentialInformation” in accordance with fluctuations in theprices of the underlying Securities in the Portfolio. Theinitial price of the Securities upon deposit by theSponsor was determined by the Trustee. The Trusteewill generally determine the value of the Securities asof the Evaluation Time on each business day and willadjust the Public Offering Price of Units accordingly.The Evaluation Time is the close of the New YorkStock Exchange on each business day. The term“business day”, as used herein and under “Rights ofUnitholders--Redemption of Units”, means any day onwhich the New York Stock Exchange is open forregular trading. The Public Offering Price per Unit willbe effect ive for al l orders received pr ior to theEvaluat ion T ime on each business day. Ordersreceived by the Sponsor prior to the Evaluation Timeand orders received by author ized f inancia lprofessionals prior to the Evaluation Time that areproperly transmitted to the Sponsor by the timedesignated by the Sponsor, are priced based on thedate of receipt. Orders received by the Sponsor afterthe Evaluat ion T ime, and orders received byauthorized financial professionals after the EvaluationTime or orders received by such persons that are not

transmitted to the Sponsor unt i l after the t imedesignated by the Sponsor, are priced based on thedate of the next determined Public Offering Price perUnit provided they are received timely by the Sponsoron such date. It is the responsibility of authorizedfinancial professionals to transmit orders received bythem to the Sponsor so they will be received in atimely manner.

The value of portfolio securities is based on thesecurities’ market price when available. When amarket pr ice is not readi ly avai lable, includingcircumstances under which the Trustee determinesthat a security’s market price is not accurate, aport fo l io secur i ty is valued at i ts fa i r value, asdetermined under procedures established by theTrustee or an independent pricing service used by theTrustee. In these cases, the Portfolio’s net asset valuewill reflect certain portfolio securities’ fair value ratherthan their market price. With respect to securities thatare primarily listed on foreign exchanges, the value ofthe portfolio securities may change on days when youwill not be able to purchase or sell Units. The value ofany foreign securities is based on the applicablecurrency exchange rate as of the Evaluation Time. TheSponsor will provide price dissemination and oversightservices to the Portfolio.

During the initial offering period, part of the PublicOffering Price represents an amount that will pay thecosts incurred in establishing your Portfolio. Thesecosts include the costs of preparing documentsrelating to the Portfolio (such as the registrationstatement, prospectus, trust agreement and legaldocuments), federal and state registration fees, feespaid to any Portfolio Consultant for assisting theSponsor in the selection of securities, the initial feesand expenses of the Trustee and the initial audit. YourPortfolio will sell securities to reimburse us for thesecosts at the end of the initial offering period or after sixmonths, if earlier. The value of your Units will declinewhen the Portfolio pays these costs.

Unit Distribution. Units will be distributed to thepublic by the Sponsor, broker-dealers and others at thePublic Offer ing Price. Units repurchased in thesecondary market, if any, may be offered by this

Page 16: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-7

prospectus at the secondary market Public OfferingPrice in the manner described above.

Unit Sales Concessions. Brokers, dealers andothers will be allowed a regular concession or agencycommission in connection with the distribution of Unitsduring the initial offering period of 1.25% of the PublicOffering Price per Unit.

Volume Concession Based Upon Annual Sales. Asdescribed below, broker-dealers and other sellingagents may in certa in cases be e l ig ib le for anadditional concession based upon their annual eligiblesales of all Invesco fixed income and equity unitinvestment trusts. Eligible sales include all units of anyInvesco uni t investment t rust underwr i t ten orpurchased directly from Invesco during a trust’s initialoffering period. For purposes of this concession,trusts designated as either “Invesco Unit Trusts,Taxable Income Series” or “Invesco Unit Trusts,Municipal Series” are fixed income trusts, and trustsdesignated as “Invesco Unit Trusts Series” are equitytrusts. In addition to the regular concessions oragency commissions described above in “Unit SalesConcessions” all broker-dealers and other sellingf i rms wi l l be e l ig ib le to receive addi t ionalcompensation based on total initial offering periodsales of all eligible Invesco unit investment trustsduring the previous consecutive 12-month periodthrough the end of the most recent month. TheVolume Concession, as applicable to equity and fixedincome trust units, is set forth in the following table:

Volume Concession____________________Total Sales Equity Trust Fixed Income (in millions) Units Trust Units______________________ ____________ ______________

$25 but less than $100 0.035% 0.035%$100 but less than $150 0.050 0.050$150 but less than $250 0.075 0.075$250 but less than $1,000 0.100 0.100$1,000 but less than $5,000 0.125 0.100$5,000 but less than $7,500 0.150 0.100$7,500 or more 0.175 0.100

Broker-dealers and other selling firms will not receivethe Volume Concession on the sale of units purchasedin Fee Accounts, however, such sales will be included

in determining whether a firm has met the sales levelbreakpoints set forth in the Volume Concession tableabove. Secondary market sales of all unit investmenttrusts are excluded for purposes of the VolumeConcession. Eligible dealer firms and other sellingagents include clearing firms that place orders withInvesco and provide Invesco with information withrespect to the representatives who initiated suchtransactions. Eligible dealer firms and other sellingagents will not include firms that solely provide clearingservices to other broker-dealer firms or firms who placeorders through clearing firms that are eligible dealers.We reserve the right to change the amount of theconcessions or agency commissions from time to time.For a trust to be el ig ible for this addit ionalcompensation, the trust’s prospectus must includedisclosure related to this additional compensation.

Additional Information. Except as provided in thissection, any sales charge discount provided toinvestors will be borne by the selling broker-dealer oragent. For all secondary market transactions the totalconcession or agency commission will amount to 80%of the applicable sales charge. Notwithstandinganything to the contrary herein, in no case shall the totalof any concessions, agency commissions and anyadditional compensation allowed or paid to any broker,dealer or other distributor of Units with respect to anyindividual transaction exceed the total sales chargeapplicable to such transaction. The Sponsor reservesthe right to reject, in whole or in part, any order for thepurchase of Units and to change the amount of theconcession or agency commission to dealers andothers from time to time.

We may provide, at our own expense and out of ourown profits, additional compensation and benefits tobroker-dealers who sell Units of the Portfolio and ourother products. This compensation is intended to resultin additional sales of our products and/or compensatebroker-dealers and financial advisors for past sales. Wemay make these payments for marketing, promotionalor related expenses, including, but not limited to,expenses of entertaining retail customers and financialadvisors, advert ising, sponsorship of events orseminars, obtaining shelf space in broker-dealer firms

Page 17: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-8

and similar activities designed to promote the sale ofthe Portfolio and our other products. Fees may includepayment for travel expenses, including lodging, incurredin connection with trips taken by invited registeredrepresentatives for meetings or seminars of a businessnature. These arrangements will not change the priceyou pay for your Units.

Sponsor Compensation. The Sponsor will receivethe total sales charge applicable to each transaction.Except as provided under “Unit Distribution,” any salescharge discount provided to investors will be borne bythe selling dealer or agent. In addition, the Sponsor willrealize a profit or loss as a result of the differencebetween the price paid for the Securities by the Sponsorand the cost of the Securities to the Portfolio on the InitialDate of Deposit as well as on subsequent deposits. See“Notes to Portfolio”. The Sponsor has not participated assole underwriter or as manager or as a member of theunderwriting syndicates or as an agent in a privateplacement for any of the Securities. The Sponsor mayrealize profit or loss as a result of the possible fluctuationsin the market value of Units held by the Sponsor for saleto the public. In maintaining a secondary market, theSponsor will realize profits or losses in the amount of anydifference between the price at which Units arepurchased and the price at which Units are resold (whichprice includes the applicable sales charge) or from aredemption of repurchased Units at a price above orbelow the purchase price. Cash, if any, made available tothe Sponsor prior to the date of settlement for thepurchase of Units may be used in the Sponsor’s businessand may be deemed to be a benefit to the Sponsor,subject to the limitations of the Securities Exchange Actof 1934, as amended (“1934 Act”).

The Sponsor or an affiliate may have participated in apublic offering of one or more of the Securities. TheSponsor, an affiliate or their employees may have a longor short position in these Securities or related securities.An affiliate may act as a specialist or market maker forthese Securities. An officer, director or employee of theSponsor or an affiliate may be an officer or director forissuers of the Securities.

Market for Units. Although it is not obligated to doso, the Sponsor may maintain a market for Units and to

purchase Units at the secondary market repurchase price(which is described under “Right of Unitholders--Redemption of Units”). The Sponsor may discontinuepurchases of Units or discontinue purchases at this priceat any time. In the event that a secondary market is notmaintained, a Unitholder will be able to dispose of Unitsby tendering them to the Trustee for redemption at theRedemption Price. See “Rights of Unitholders--Redemption of Units”. Unitholders should contact theirbroker to determine the best price for Units in thesecondary market. Units sold prior to the time the entiredeferred sales charge has been collected will beassessed the amount of any remaining deferred salescharge at the time of sale. The Trustee will notify theSponsor of any Units tendered for redemption. If theSponsor’s bid in the secondary market equals orexceeds the Redemption Price per Unit, it may purchasethe Units not later than the day on which Units wouldhave been redeemed by the Trustee. The Sponsor maysell repurchased Units at the secondary market PublicOffering Price per Unit.

RETIREMENT ACCOUNTS

Units are available for purchase in connection withcertain types of tax-sheltered retirement plans, includingIndividual Retirement Accounts for individuals, SimplifiedEmployee Pension Plans for employees, qualified plansfor self-employed individuals, and qualified corporatepension and profit sharing plans for employees. Theminimum purchase for these accounts is reduced to 25Units but may vary by selling firm. The purchase ofUnits may be limited by the plans’ provisions and doesnot itself establish such plans.

FEE ACCOUNTS

As described above, Units may be available forpurchase by investors in Fee Accounts where thePortfolio is Wrap Fee Eligible. You should consult yourfinancial professional to determine whether you canbenefit from these accounts. This table illustrates thesales charge you will pay if the Portfolio is Wrap FeeEligible as a percentage of the initial Public OfferingPrice per Unit on the Initial Date of Deposit (thepercentage will vary thereafter).

Page 18: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-9

Initial sales charge 0.00%Deferred sales charge 0.00______

Transactional sales charge 0.00%____________Creation and development fee 0.50%______

Total sales charge 0.50%____________

You should consult the “Public Offering--Reducing YourSales Charge” section for specific information on this andother sales charge discounts. That section governs thecalculation of all sales charge discounts. The Sponsorreserves the right to limit or deny purchases of Units inFee Accounts by investors or selling firms whose frequenttrading activity is determined to be detrimental to thePortfolio. To purchase Units in these Fee Accounts, yourfinancial professional must purchase Units designatedwith one of the Wrap Fee CUSIP numbers set forth under“Essential Information,” either Wrap Fee Cash for cashdistributions or Wrap Fee Reinvest for the reinvestment ofdistributions in additional Units, if available. See “Rights ofUnitholders--Reinvestment Option.”

RIGHTS OF UNITHOLDERS

Distributions. Dividends and interest, net ofexpenses, and any net proceeds from the sale ofSecurities received by the Portfolio will generally bedistributed to Unitholders on each Distribution Date toUnitholders of record on the preceding Record Date.These dates appear under “Essential Information”.Distributions made by the securities in your Portfolioinclude ordinary income, but may also include sourcesother than ordinary income such as returns of capital,loan proceeds, short-term capital gains and long-termcapital gains (see “Taxation--Distributions”). In addition,the Portfolio will generally make required distributions atthe end of each year because it is structured as a“regulated investment company” for federal taxpurposes. Unitholders wi l l also receive a f inaldistribution of income when the Portfolio terminates. Aperson becomes a Unitholder of record on the date ofsettlement (generally two business days after Units areordered, or any shorter period as may be required bythe applicable rules under the 1934 Act). Unitholders

may elect to receive distributions in cash or to havedistributions reinvested into additional Units. See“Rights of Unitholders--Reinvestment Option”.

Dividends and interest received by the Portfolio arecredited to the Income Account of the Portfolio. Otherreceipts (e.g., capital gains, proceeds from the sale ofSecurities, etc.) are credited to the Capital Account.Proceeds received on the sale of any Securities, to theextent not used to meet redemptions of Units or paydeferred sales charges, fees or expenses, will bedistributed to Unitholders. Proceeds received from thedisposition of any Securities after a Record Date andprior to the following Distribution Date will be held in theCapital Account and not distributed until the nextDistribution Date. Any distribution to Unitholdersconsists of each Unitholder’s pro rata share of theavailable cash in the Income and Capital Accounts as ofthe related Record Date.

Estimated Distributions. The estimated initialdistribution and estimated net annual income per Unitmay be shown under “Essent ia l Informat ion.”Generally, the estimate of the income the Portfolio mayreceive is based on the most recent ordinary quarterlydividends declared by an issuer, the most recentinterim and final dividends declared for certain foreignissuers, or scheduled income payments (in all casesaccounting for any applicable foreign withholdingtaxes). In certain cases, estimated net annual incomemay also be based upon several recently declareddividends of an issuer. However, common stocks donot assure dividend payments and therefore theamount of future dividend income to your Portfolio isuncertain. The actual net annual distributions maydecrease over time because a portion of the Securitiesincluded in the Portfolio will be sold to pay for theorganization costs, deferred sales charge and creationand development fee. Securities may also be sold topay regular fees and expenses during the Portfolio’slife. Dividend and income conventions for certaincompanies and/or certain countries differ from thosetypically used in the United States and in certaininstances, dividends/income paid or declared overseveral years or other per iods may be used toestimate annual distributions. The actual net annual

Page 19: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-10

income distributions you receive will vary from theestimated amount due to changes in the Portfolio’sfees and expenses, in actual income received by thePortfolio, currency fluctuations and with changes inthe Portfolio such as the acquisition, call, maturity orsale of Securities. Due to these and various otherfactors, actual income received by the Portfolio willmost likely differ from the most recent dividends orscheduled income payments.

Reinvestment Option. Unitholders may havedistributions automatically reinvested in additionalUnits without a sales charge (to the extent Units maybe lawfully offered for sale in the state in which theUnitholder resides). The CUSIP numbers for either“Cash” distributions or “Reinvest” for the reinvestmentof d ist r ibut ions are set forth under “Essent ia lInformation”. Brokers and dealers can use theDividend Reinvestment Service through DepositoryTrust Company (“DTC”) or purchase a Reinvest (orWrap Fee Reinvest in the case of Wrap Fee EligibleUnits held in Fee Accounts) CUSIP, if available. Toparticipate in this reinvestment option, a Unitholdermust file with the Trustee a written notice of election,together with any other documentation that theTrustee may then require, at least five days prior tothe related Record Date. A Unitholder’s election willapply to all Units owned by the Unitholder and willremain in effect until changed by the Unitholder. Thereinvestment option is not offered during the 30calendar days prior to termination. I f Units areunavailable for reinvestment or this reinvestmentoption is no longer available, distributions will be paidin cash. Distributions will be taxable to Unitholders ifpaid in cash or automatically reinvested in additionalUnits. See “Taxation”.

A participant may elect to terminate his or herreinvestment plan and receive future distributions incash by notifying the Trustee in writing no later thanfive days before a Distribution Date. The Sponsor shallhave the r ight to suspend or terminate thereinvestment plan at any time. The reinvestment planis subject to availability or limitation by each broker-dealer or selling firm. Broker-dealers may suspend orterminate the offering of a reinvestment plan at any

time. Please contact your financial professional foradditional information.

Redemption of Units. All or a portion of your Unitsmay be tendered to The Bank of New York Mellon, theTrustee, for redemption at Unit Investment TrustDivision, 111 Sanders Creek Parkway, East Syracuse,New York 13057, on any day the New York StockExchange is open. No redemption fee will be chargedby the Sponsor or the Trustee, but you are responsiblefor applicable governmental charges, if any. Unitsredeemed by the Trustee will be canceled. You mayredeem all or a portion of your Units by sending arequest for redemption to your bank or broker-dealerthrough which you hold your Units. No later than twobusiness days (or any shorter period as may berequired by the applicable rules under the 1934 Act)following satisfactory tender, the Unitholder will beentitled to receive in cash an amount for each Unitequal to the Redemption Price per Unit next computedon the date of tender. The “date of tender” is deemed tobe the date on which Units are received by the Trustee,except that with respect to Units received by theTrustee after the Evaluation Time or on a day which isnot a business day, the date of tender is deemed to bethe next business day. Redemption requests receivedby the Trustee after the Evaluation T ime, andredemption requests received by authorized financialprofessionals after the Evaluation Time or redemptionrequests received by such persons that are nottransmitted to the Trustee until after the time designatedby the Trustee, are priced based on the date of the nextdetermined redemption price provided they are receivedtimely by the Trustee on such date. It is theresponsibility of authorized financial professionals totransmit redemption requests received by them to theTrustee so they will be received in a timely manner.Certain broker-dealers or selling firms may charge anorder handling fee for processing redemption requests.Units redeemed directly through the Trustee are notsubject to such fees.

Unitholders tendering 1,000 or more Units of thePortfolio (or such higher amount as may be required byyour broker-dealer or selling agent) for redemption mayrequest an in kind distribution of Securities equal to the

Page 20: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-11

Redemption Price per Unit on the date of tender.Unitholders may not request an in kind distribution duringthe initial offering period or within 30 calendar days of thePortfolio’s termination. The Portfolio generally will not offerin kind distributions of portfolio securities that are held inforeign markets. An in kind distribution will be made by theTrustee through the distribution of each of the Securities inbook-entry form to the account of the Unitholder’s broker-dealer at DTC. Amounts representing fractional shares willbe distributed in cash. The Trustee may adjust the numberof shares of any Security included in a Unitholder’s in kinddistribution to facilitate the distribution of whole shares.The in kind distribution option may be modified ordiscontinued at any time without notice. Notwithstandingthe foregoing, if the Unitholder requesting an in kinddistribution is the Sponsor or an affiliated person of thePortfolio, the Trustee may make an in kind distribution tosuch Unitholder provided that no one with a pecuniaryincentive to influence the in kind distribution may influenceselection of the distributed securities, the distribution mustconsist of a pro rata distribution of all portfolio securities(with limited exceptions) and the in kind distribution maynot favor such affiliated person to the detriment of anyother Unitholder. Unitholders will incur transaction costs inliquidating securities received in an in-kind distribution,and any such securities received will be subject to marketrisk until sold. In the event that any securities received in-kind are illiquid, Unitholders will bear the risk of not beingable to sell such securities in the near term, or at all.

The Trustee may sell Securities to satisfy Unitredemptions. To the extent that Securit ies areredeemed in kind or sold, the size of the Portfolio willbe, and the diversity of the Portfolio may be, reduced.Sales may be required at a time when Securities wouldnot otherwise be sold and may result in lower pricesthan might otherwise be realized. The price receivedupon redemption may be more or less than the amountpaid by the Unitholder depending on the value of theSecurities at the time of redemption. Special federalincome tax consequences will result if a Unitholderrequests an in kind distribution. See “Taxation”.

The Redemption Price per Unit and the secondarymarket repurchase price per Unit are equal to the prorata share of each Unit in the Portfolio determined on

the basis of (i) the cash on hand in the Portfolio, (ii) thevalue of the Securities in the Portfolio and (iii) dividendsor other income distr ibutions receivable on theSecurities in the Portfolio trading ex-dividend as of thedate of computation, less (a) amounts representingtaxes or other governmental charges payable out of thePortfolio, (b) the accrued expenses of the Portfolio(including costs associated with liquidating securitiesafter the end of the initial offering period) and (c) anyunpaid deferred sales charge payments. During theinitial offering period, the redemption price and thesecondary market repurchase price are not reduced bythe estimated organization costs or the creation anddevelopment fee. For these purposes, the Trustee willdetermine the value of the Securities as describedunder “Public Offering--Unit Price”.

The right of redemption may be suspended andpayment postponed for any period during which theNew York Stock Exchange is closed, other than forcustomary weekend and holiday closings, or any periodduring which the SEC determines that trading on thatExchange is restricted or an emergency exists, as aresult of which disposal or evaluation of the Securities isnot reasonably practicable, or for other periods as theSEC may permit.

Exchange Option. When you redeem Units of yourPortfol io or when your Portfol io terminates (see“Rollover” below), you may be able to exchange yourUnits for units of other Invesco unit trusts. You shouldcontact your financial professional for more informationabout trusts currently available for exchanges. Beforeyou exchange Units, you should read the prospectus ofthe new trust carefully and understand the risks andfees. You should then discuss this option with yourfinancial professional to determine whether yourinvestment goals have changed, whether current trustssuit you and to discuss tax consequences. A rollover orexchange is a taxable event to you. We may discontinuethis option at any time.

Rollover. We may offer a subsequent series of thePortfolio, for a Rollover when the Portfolio terminates.

On the Mandatory Termination Date you will have theoption to (1) participate in a Rollover and have your

Page 21: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-12

Units reinvested into a subsequent trust series or (2) receive a cash distribution.

If you elect to participate in a cash Rollover, yourUnits will be redeemed on the Mandatory TerminationDate. As the redemption proceeds become available,the proceeds (including dividends) will be invested in anew trust series at the public offering price for the newtrust. The Trustee will attempt to sell Securities to satisfythe redemption as quickly as practicable on theMandatory Termination Date. We do not anticipate thatthe sale period will be longer than one day, however,certain factors could affect the ability to sell theSecurities and could impact the length of the saleperiod. The liquidity of any Security depends on thedaily trading volume of the Security and the amountavailable for redemption and reinvestment on any day.

We may make subsequent trust series available forsale at various times during the year. Of course, wecannot guarantee that a subsequent trust or sufficientunits will be available or that any subsequent trusts willoffer the same investment strategy or objective as thecurrent Portfolio. We cannot guarantee that a Rollover willavoid any negative market price consequences resultingfrom trading large volumes of securities. Market pricetrends may make it advantageous to sell or buy securitiesmore quickly or more slowly than permitted by thePortfolio procedures. We may, in our sole discretion,modify a Rollover or stop creating units of a trust at anytime regardless of whether all proceeds of Unitholdershave been reinvested in a Rollover. If we decide not tooffer a subsequent series, Unitholders will be notifiedprior to the Mandatory Termination Date. Cash which hasnot been reinvested in a Rollover will be distributed toUnitholders shortly after the Mandatory Termination Date.Rollover participants may receive taxable dividends orrealize taxable capital gains which are reinvested inconnection with a Rollover but may not be entitled to adeduction for capital losses due to the “wash sale” taxrules. Due to the reinvestment in a subsequent trust, nocash will be distributed to pay any taxes. See “Taxation”.

Units. Ownership of Units is evidenced in book-entryform only and will not be evidenced by certificates. Unitspurchased or held through your bank or broker-dealer willbe recorded in book-entry form and credited to the

account of your bank or broker-dealer at DTC. Units aretransferable by contacting your bank or broker-dealerthrough which you hold your Units. Transfer, and therequirements therefore, wil l be governed by theapplicable procedures of DTC and your agreement withthe DTC participant in whose name your Units areregistered on the transfer records of DTC.

Reports Provided. Unitholders will receive astatement of dividends and other amounts received bythe Portfolio for each distribution. Within a reasonabletime after the end of each year, each person who was aUnitholder during that year will receive a statementdescribing dividends and capital received, actualPortfolio distributions, Portfolio expenses, a list of theSecurities and other Portfolio information. Unitholdersmay obtain evaluations of the Securities upon requestto the Trustee. If you have questions regarding youraccount or your Portfolio, please contact your financialadvisor or the Trustee. The Sponsor does not haveaccess to individual account information.

PORTFOLIO ADMINISTRATION

Portfolio Administration. The Portfolio is not amanaged fund and, except as provided in the TrustAgreement, Securities generally will not be sold orreplaced. The Sponsor may, however, direct thatSecurities be sold in certain limited circumstances toprotect the Portfol io based on advice from theSupervisor. These situations may include events such asthe issuer having defaulted on payment of any of itsoutstanding obligations or the price of a Security hasdeclined to such an extent or other credit factors existso that in the opinion of the Supervisor retention of theSecurity would be detrimental to the Portfolio. If a publictender offer has been made for a Security or a merger oracquisition has been announced affecting a Security, theTrustee may either sell the Security or accept an offer ifthe Supervisor determines that the sale or exchange is inthe best interest of Unitholders. The Trustee willdistribute any cash proceeds to Unitholders. In addition,the Trustee may sell Securities to redeem Units or payPortfol io expenses or deferred sales charges. Ifsecurities or property are acquired by the Portfolio, theSponsor may direct the Trustee to sell the securities or

Page 22: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-13

property and distribute the proceeds to Unitholders or toaccept the securities or property for deposit in thePortfolio. Should any contract for the purchase of any ofthe Securities fail, the Sponsor will (unless substantiallyall of the moneys held in the Portfolio to cover thepurchase are reinvested in substitute Securities inaccordance with the Trust Agreement) refund the cashand sales charge attributable to the failed contract to allUnitholders on or before the next Distribution Date.

The Sponsor may direct the reinvestment ofproceeds of the sale of Securities if the sale is the directresult of serious adverse credit factors which, in theopinion of the Sponsor, would make retention of theSecurities detrimental to the Portfolio. In such a case,the Sponsor may, but is not obligated to, direct thereinvestment of sale proceeds in any other securitiesthat meet the criteria for inclusion in the Portfolio on theInitial Date of Deposit. The Sponsor may also instructthe Trustee to take action necessary to ensure that thePortfolio continues to satisfy the qualifications of aregulated investment company and to avoid impositionof tax on undistributed income of the Portfolio.

When your Portfolio sells Securities, the compositionand diversity of the Securities in the Portfolio may bealtered. In order to obtain the best price for thePortfolio, it may be necessary for the Supervisor tospecify minimum amounts (generally 100 shares) inwhich blocks of Securities are to be sold. In effectingpurchases and sales of portfolio securities, the Sponsormay direct that orders be placed with and brokeragecommissions be paid to brokers, including brokerswhich may be affiliated with the Portfolio, the Sponsoror dealers participating in the offering of Units.

Pursuant to an exemptive order, your Portfolio maybe permitted to sell Securities to a new trust when itterminates if those Securities are included in the newtrust. The exemption may enable your Portfolio toeliminate commission costs on these transactions. Theprice for those securities will be the closing sale priceon the sale date on the exchange where the Securitiesare principally traded, as certified by the Sponsor.

Amendment of the Trust Agreement. The Trusteeand the Sponsor may amend the Trust Agreement

without the consent of Unitholders to correct anyprovision which may be defective or to make otherprovisions that will not materially adversely affectUnitholders (as determined in good faith by the Sponsorand the Trustee). The Trust Agreement may not beamended to increase the number of Units or permitacquisition of securities in addition to or substitution forthe Securities (except as provided in the Trust Agreement).The Trustee will notify Unitholders of any amendment.

Termination. The Portfolio will terminate on theMandatory Termination Date specified under “EssentialInformation” or upon the sale or other disposition of thelast Security held in the Portfolio. The Portfolio may beterminated at any time with consent of Unitholdersrepresenting two-thirds of the outstanding Units or bythe Trustee when the value of the Portfolio is less than$500,000 ($3,000,000 if the value of the Portfolio hasexceeded $15,000,000) (the “Minimum TerminationValue”). The Portfolio will be liquidated by the Trustee inthe event that a sufficient number of Units of thePortfolio not yet sold are tendered for redemption bythe Sponsor, so that the net worth of the Portfoliowould be reduced to less than 40% of the value of theSecurities at the time they were deposited in thePortfolio. If the Portfolio is liquidated because of theredemption of unsold Units by the Sponsor, theSponsor will refund to each purchaser of Units theentire sales charge paid by such purchaser. The Trusteemay begin to sell Securities in connection with thePortfolio termination nine business days before, and nolater than, the Mandatory Termination Date. QualifiedUnitholders may elect an in kind distr ibution ofSecurities, provided that Unitholders may not requestan in kind distribution of Securities within 30 calendardays of the Portfol io’s termination. Any in kinddistribution of Securities will be made in the manner andsubject to the restrictions described under “Rights ofUnitholders--Redemption of Units”, provided that, inconnection with an in kind distribution election morethan 30 calendar days prior to termination, Unitholderstendering 1,000 or more Units of the Portfolio (or suchhigher amount as may be required by your broker-dealer or sel l ing agent) may request an in kinddistribution of Securities equal to the Redemption Price

Page 23: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-14

per Unit on the date of tender. Unitholders will receive afinal cash distribution within a reasonable time after theMandatory Termination Date. All distributions will be netof the Portfolio’s expenses and costs. Unitholders willreceive a f inal distr ibution statement fol lowingtermination. The Information Supplement containsfurther information regarding termination of the Portfolio.See “Additional Information”.

Limitations on Liabilities. The Sponsor,Supervisor and Trustee are under no liability for takingany action or for refraining from taking any action in goodfaith pursuant to the Trust Agreement, or for errors injudgment, but shall be liable only for their own willfulmisfeasance, bad faith or gross negligence (negligence inthe case of the Trustee) in the performance of their dutiesor by reason of their reckless disregard of theirobligations and duties hereunder. The Trustee is not liablefor depreciation or loss incurred by reason of the sale bythe Trustee of any of the Securities. In the event of thefailure of the Sponsor to act under the Trust Agreement,the Trustee may act thereunder and is not liable for anyaction taken by it in good faith under the TrustAgreement. The Trustee is not liable for any taxes orother governmental charges imposed on the Securities,on it as Trustee under the Trust Agreement or on thePortfolio which the Trustee may be required to pay underany present or future law of the United States of Americaor of any other taxing authority having jurisdiction. Inaddition, the Trust Agreement contains other customaryprovisions limiting the liability of the Trustee. The Sponsorand Supervisor may rely on any evaluation furnished bythe Trustee and have no responsibility for the accuracythereof. Determinations by the Trustee shall be made ingood faith upon the basis of the best informationavailable to it.

Sponsor. Invesco Capital Markets, Inc. is theSponsor of your Portfolio. The Sponsor is a whollyowned subsidiary of Invesco Advisers, Inc. (“InvescoAdvisers”). Invesco Advisers is an indirect wholly ownedsubsidiary of Invesco Ltd., a leading independent globalinvestment manager that provides a wide range ofinvestment strategies and vehicles to its retail, institutionaland high net worth clients around the globe. TheSponsor’s principal office is located at 11 Greenway

Plaza, Houston, Texas 77046-1173. As of December 31,2017, the total stockholders’ equity of Invesco CapitalMarkets, Inc. was $100,102,806.15 (unaudited). Thecurrent assets under management and supervision byInvesco Ltd. and its affi l iates were valued atapproximately $937.6 billion as of December 31, 2017.

The Sponsor and your Portfolio have adopted a codeof ethics requiring Invesco Ltd.’s employees who haveaccess to information on Portfolio transactions to reportpersonal securities transactions. The purpose of thecode is to avoid potential conflicts of interest and toprevent fraud, deception or misconduct with respect toyour Portfolio. The Information Supplement containsadditional information about the Sponsor.

If the Sponsor shall fail to perform any of its dutiesunder the Trust Agreement or become incapable ofacting or shall become bankrupt or its affairs are takenover by public authorities, then the Trustee may ( i ) appoint a successor Sponsor at rates ofcompensat ion deemed by the Trustee to bereasonable and not exceeding amounts prescribed bythe SEC, ( i i ) terminate the Trust Agreement andl iquidate the Port fo l io as provided therein or (iii) continue to act as Trustee without terminating theTrust Agreement.

Trustee. The Trustee is The Bank of New YorkMellon, a trust company organized under the laws ofNew York. The Bank of New York Mellon has itsprincipal unit investment trust division offices at 2 Hanson Place, 12th Floor, Brooklyn, New York 11217,(800) 856-8487. If you have questions regarding youraccount or your Portfolio, please contact the Trustee atits principal unit investment trust division offices or yourfinancial adviser. The Sponsor does not have access toindividual account information. The Bank of New YorkMellon is subject to supervision and examination by theSuperintendent of Banks of the State of New York andthe Board of Governors of the Federal Reserve System,and its deposits are insured by the Federal DepositInsurance Corporation to the extent permitted by law.Additional information regarding the Trustee is set forthin the Information Supplement, including the Trustee’squalifications and duties, its ability to resign, the effectof a merger involving the Trustee and the Sponsor’s

Page 24: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-15

abi l i ty to remove and replace the Trustee. See“Additional Information”.

TAXATION

This section summarizes some of the principal U.S.federal income tax consequences of owning Units ofthe Portfolio. Tax laws and interpretations are subject tochange, possibly with retroactive effect. Substantialchanges to the federal tax law were passed and signedinto law in December 2017, many of which becomeeffective in 2018 and may affect your investment in aPortfolio in a number of ways, including possibleunintended consequences. This summary does notdescribe all of the tax consequences to all taxpayers.For example, this summary generally does not describeyour situation if you are a corporation, a non-U.S.person, a broker/dealer, a tax-exempt entity, financialinstitution, person who marks to market their Units orother investor with special circumstances. In addition,this section does not describe your alternativeminimum, state, local or foreign tax consequences ofinvesting in the Portfolio.

This federal income tax summary is based in part onthe advice of counsel to the Sponsor. The InternalRevenue Service could disagree with any conclusionsset forth in this section. In addition, our counsel was notasked to review the federal income tax treatment of theassets to be deposited in the Portfolio.

Additional information related to taxes is contained inthe Information Supplement. As with any investment,you should seek advice based on your individualcircumstances from your own tax advisor.

Portfolio Status. Your Portfolio intends to electand to qualify annually as a “regulated investmentcompany” (“RIC”) under the federal tax laws. If yourPortfolio qualifies under the tax law as a RIC anddistributes its income in the manner and amountsrequired by the RIC tax requirements, the Portfoliogenerally will not pay federal income taxes. But there isno assurance that the distributions made by yourPortfolio will eliminate all taxes for every year at the levelof your Portfolio.

Distributions. Portfolio distributions are generallytaxable to you. After the end of each year, you willreceive a tax statement reporting your Portfolio’sdistributions, including the amounts of ordinary incomedistributions and capital gains dividends. Your Portfoliomay make taxable distributions to you even in periodsduring which the value of your Units has declined.Ordinary income distributions are generally taxed at yourfederal tax rate for ordinary income, however, as furtherdiscussed below, certain ordinary income distributionsreceived from your Portfolio may be taxed, under currentfederal law, at the capital gains tax rates. Certainordinary income dividends on Units that are attributableto qualifying dividends received by your Portfolio fromcertain corporations may be reported by the Portfolio asbeing eligible for the dividends received deduction forcorporate Unitholders provided certain holding periodrequirements are met. Income from the Portfolio andgains on the sale of your Units may also be subject to a3.8% federal tax imposed on net investment income ifyour adjusted gross income exceeds certain thresholdamounts, which are $250,000 in the case of marriedcouples filing joint returns and $200,000 in the case ofsingle individuals. In addition, your Portfolio may makedistributions that represent a return of capital for taxpurposes to the extent of the Unitholder’s basis in theUnits, and any additional amounts in excess of basiswould be taxed as a capital gain. Generally, you will treatall capital gains dividends as long-term capital gainsregardless of how long you have owned your Units. Thetax status of your distributions from your Portfolio is notaffected by whether you reinvest your distributions inadditional Units or receive them in cash. The incomefrom your Portfolio that you must take into account forfederal income tax purposes is not reduced by amountsused to pay a deferred sales charge, if any. The tax lawsmay require you to treat certain distributions made toyou in January as if you had received them onDecember 31 of the previous year.

A distribution paid by your Portfolio reduces thePortfolio’s net asset value per Unit on the date paid bythe amount of the distr ibut ion. Accordingly, adistribution paid shortly after a purchase of Units by aUnitholder would represent, in substance, a partial

Page 25: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-16

return of capital, however, it would be subject toincome taxes.

Sale or Redemption of Units. If you sell orredeem your Units, you will generally recognize a taxablegain or loss. To determine the amount of this gain orloss, you must subtract your adjusted tax basis in yourUnits from the amount you receive in the transaction.Your initial tax basis in your Units is generally equal to thecost of your Units, generally including sales charges. Insome cases, however, you may have to adjust your taxbasis after you purchase your Units.

Capital Gains and Losses and CertainOrdinary Income Dividends. Net capital gain equalsnet long-term capital gain minus net short-term capitalloss for the taxable year. Capital gain or loss is long-term if the holding period for the asset is more thanone year and is short-term if the holding period for theasset is one year or less. You must exclude the dateyou purchase your Units to determine your holdingperiod. However, if you receive a capital gain dividendfrom your Portfolio and sell your Units at a loss afterholding it for six months or less, the loss will berecharacterized as long-term capital loss to the extentof the capital gain dividend received. The tax rates forcapital gains realized from assets held for one year orless are generally the same as for ordinary income.

In certain circumstances, ordinary income dividendsreceived by an individual Unitholder from a regulatedinvestment company such as the Portfolio may betaxed at the same federal rates that apply to net capitalgain (as discussed above), provided certain holdingperiod requirements are satisfied and provided thedividends are attributable to qualified dividend incomereceived by the Portfolio itself. Your Portfolio will providenotice to its Unitholders of the amount of anydistribution which may be taken into account asqualified dividend income which is eligible for the capitalgains tax rates. There is no requirement that taxconsequences be taken into account in administeringyour Portfolio.

In Kind Distributions. Under certain circumstances,as described in this prospectus, you may receive an inkind distribution of Portfolio securities when you redeem

your Units. In general, this distribution will be treated as asale for federal income tax purposes and you willrecognize gain or loss, based on the value at that time ofthe securities and the amount of cash received, andsubject to certain limitations on the deductibility of lossesunder the tax law.

Rollovers and Exchanges. If you elect to have yourproceeds from your Portfolio rolled over into a future trust,it would generally be considered a sale for federal incometax purposes and any gain on the sale will be treated as acapital gain, and, in general, any loss will be treated as acapital loss. However, any loss realized on a sale orexchange will be disallowed to the extent that Unitsdisposed of are replaced (including through reinvestmentof dividends) within a period of 61 days beginning 30 daysbefore and ending 30 days after disposition of Units or tothe extent that the Unitholder, during such period,acquires or enters into an option or contract to acquire,substantially identical stock or securities. In such a case,the basis of the Units acquired will be adjusted to reflectthe disallowed loss. The deductibility of capital losses issubject to other limitations in the tax law.

Deductibility of Portfolio Expenses. Expensesincurred and deducted by your Portfolio will generally notbe treated as income taxable to you. In some cases,however, you may be required to treat your portion ofthese Portfolio expenses as income. In these cases youmay be able to take a deduction for these expenses.Recent legislation, effective in 2018, has suspended thedeductibility of expenses that are characterized asmiscellaneous itemized deductions, which includeinvestment expenses.

Foreign Investors. If you are a foreign investor(i.e., an investor other than a U.S. citizen or resident ora U.S. corporation, partnership, estate or trust),generally, subject to applicable tax treaties, distributionsto you from the Portfolio will be characterized asdividends for federal income tax purposes (other thandividends which the Portfolio reports as capital gaindividends) and will be subject to U.S. income taxes,including withholding taxes, subject to certainexceptions described below. You may be eligible undercertain income tax treaties for a reduction in withholdingrates. However distributions received by a foreign

Page 26: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-17

investor from the Portfolio that are properly reported bythe trust as capital gain dividends may not be subject toU.S. federal income taxes, including withholding taxes,provided that the Portfolio makes certain elections andcertain other conditions are met.

The Foreign Account Tax Compliance Act(“FATCA”). A 30% withholding tax on your Portfolio’sdistributions, including capital gains distributions, and ongross proceeds from the sale or other disposition of Unitsgenerally applies if paid to a foreign entity unless: (i) if theforeign entity is a “foreign financial institution” as definedunder FATCA, the foreign entity undertakes certain duediligence, reporting, withholding, and certificationobligations, (ii) if the foreign entity is not a “foreignfinancial institution,” it identifies certain of its U.S.investors or (iii) the foreign entity is otherwise exceptedunder FATCA. If required under the rules above andsubject to the applicability of any intergovernmentalagreements between the United States and the relevantforeign country, withholding under FATCA applies: (i) withrespect to distributions from your Portfolio and (ii) withrespect to certain capital gains distributions and grossproceeds from a sale or disposition of Units that occur onor after January 1, 2019. If withholding is required underFATCA on a payment related to your Units, investors thatotherwise would not be subject to withholding (or thatotherwise would be entitled to a reduced rate ofwithholding) on such payment generally will be requiredto seek a refund or credit from the IRS to obtain thebenefit of such exemption or reduction. Your Portfolio willnot pay any additional amounts in respect of amountswithheld under FATCA. You should consult your taxadvisor regarding the effect of FATCA based on yourindividual circumstances.

Foreign Tax Credit. If the Portfolio invests in anyforeign securities, the tax statement that you receivemay include an item showing foreign taxes the Portfoliopaid to other countries. In this case, dividends taxed toyou will include your share of the taxes the Portfolio paidto other countries. You may be able to deduct or receivea tax credit for your share of these taxes if the Portfoliomeets certain requirements for passing through suchdeductions or credits to you.

Backup Withholding. By law, your Portfolio mustwithhold as backup withholding a percentage (currently24%) of your taxable distributions and redemptionproceeds if you do not provide your correct socialsecurity or taxpayer identification number and certifythat you are not subject to backup withholding, or if theIRS instructs your Portfolio to do so.

Investors should consult their advisors concerningthe federal, state, local and foreign tax consequences ofinvesting in the Portfolio.

PORTFOLIO OPERATING EXPENSES

General. The fees and expenses of your Portfolio willgenerally accrue on a daily basis. Portfolio operating feesand expenses are generally paid out of the IncomeAccount to the extent funds are available, and then fromthe Capital Account. The deferred sales charge, creationand development fee and organization costs aregenerally paid out of the Capital Account of yourPortfolio. It is expected that Securities will be sold to paythese amounts which will result in capital gains or lossesto Unitholders. See “Taxation”. These sales will reducefuture income distributions. The Sponsor’s, Supervisor’sand Trustee’s fees may be increased without approval ofthe Unitholders by amounts not exceeding proportionateincreases under the category “Services Less Rent ofShelter” in the Consumer Price Index for All UrbanConsumers or, if this category is not published, in acomparable category.

Organization Costs. You and the other Unitholderswill bear all or a portion of the organization costs andcharges incurred in connection with the establishment ofyour Portfolio. These costs and charges will include thecost of the preparation, printing and execution of the trustagreement, registration statement and other documentsrelating to your Portfolio, federal and state registration feesand costs, fees paid to any Portfolio Consultant forassisting the Sponsor in the selection of securities, theinitial fees and expenses of the Trustee, and legal andauditing expenses. The Public Offering Price of Unitsincludes the estimated amount of these costs. TheTrustee will deduct these expenses from your Portfolio’sassets at the end of the initial offering period.

Page 27: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-18

Creation and Development Fee. The Sponsorwill receive a fee from your Portfolio for creating anddeveloping the Portfolio, including determining thePortfolio’s objectives, policies, composition and size,selecting service providers and information services andfor providing other similar administrative and ministerialfunctions. The creation and development fee is a chargeof $0.05 per Unit. The Trustee will deduct this amountfrom your Portfolio’s assets as of the close of the initialoffering period. No portion of this fee is applied to thepayment of distribution expenses or as compensationfor sales efforts. This fee will not be deducted fromproceeds received upon a repurchase, redemption orexchange of Units before the close of the initial publicoffering period.

Trustee’s Fee. For its services the Trustee willreceive the fee from your Portfolio set forth in the “FeeTable” (which includes the estimated amount ofmiscellaneous Portfolio expenses). The Trustee benefitsto the extent there are funds in the Capital and IncomeAccounts since these Accounts are non-interest bearingto Unitholders and the amounts earned by the Trusteeare retained by the Trustee. Part of the Trustee’scompensation for its services to your Portfolio isexpected to result from the use of these funds.

Compensation of Sponsor and Supervisor. TheSponsor and the Supervisor, which is an affiliate of theSponsor, will receive the annual fees for providingbookkeeping and administrative services and portfoliosupervisory services set forth in the “Fee Table”. Thesefees may exceed the actual costs of providing theseservices to your Portfolio but at no time will the totalamount received for these services rendered to allInvesco unit investment trusts in any calendar yearexceed the aggregate cost of providing these servicesin that year.

Miscellaneous Expenses. The following additionalcharges are or may be incurred by your Portfolio: (a) normal expenses (including the cost of mailing reportsto Unitholders) incurred in connection with the operationof the Portfolio, (b) fees of the Trustee for extraordinaryservices, (c) expenses of the Trustee (including legal andauditing expenses) and of counsel designated by theSponsor, (d) various governmental charges, (e) expenses

and costs of any action taken by the Trustee to protectthe Portfolio and the rights and interests of Unitholders,(f) indemnification of the Trustee for any loss, liability orexpenses incurred in the administration of the Portfoliowithout negligence, bad faith or wilful misconduct on itspart, (g) foreign custodial and transaction fees (whichmay include compensation paid to the Trustee or itssubsidiaries or affiliates), (h) costs associated withliquidating the securities held in the Portfolio, (i) anyoffering costs incurred after the end of the initial offeringperiod and (j) expenditures incurred in contactingUnitholders upon termination of the Portfolio. ThePortfolio will pay a license fee to the Portfolio Consultantfor the use of certain service marks and other intellectualproperty. The Portfolio may pay the expenses ofupdating its registration statement each year.

OTHER MATTERS

Legal Opinions. The legality of the Units offeredhereby has been passed upon by Paul Hastings LLP.Dorsey & Whitney LLP has acted as counsel to theTrustee.

Independent Registered Public AccountingFirm. The statement of condition and the relatedportfol io included in this prospectus have beenaudi ted by Grant Thornton LLP, independentregistered public accounting firm, as set forth in theirreport in this prospectus, and are included herein inreliance upon the authority of said firm as experts inaccounting and auditing.

ADDITIONAL INFORMATION

This prospectus does not contain all the informationset forth in the registration statements filed by yourPortfolio with the SEC under the Securities Act of1933 and the Investment Company Act of 1940 (fileno. 811-2754). The Information Supplement, whichhas been filed with the SEC and is incorporated hereinby reference, includes more detailed informationconcerning the Securit ies, investment risks andgeneral information about the Portfolio. Informationabout your Port fo l io ( including the Informat ionSupplement) can be reviewed and copied at the SEC’s

Page 28: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

A-19

Public Reference Room in Washington, DC. You mayobtain information about the Public Reference Roomby cal l ing 1-202-551-8090. Reports and otherinformation about your Portfolio are available on theEDGAR Database on the SEC’s Internet site athttp://www.sec.gov. Copies of this information may beobtained, after paying a duplication fee, by electronicrequest at the fo l lowing e-mai l address:[email protected] or by writing the SEC’s PublicReference Section, Washington, DC 20549-0102.

Page 29: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

THIS PAGE INTENTIONALLY LEFT BLANK.

Page 30: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

THIS PAGE INTENTIONALLY LEFT BLANK.

Page 31: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

THIS PAGE INTENTIONALLY LEFT BLANK.

Page 32: Policy Opportunities Portfolio 2018-1 · Portfolio seeks to provide the potential for above-average capital ... 18 Vertex Pharmaceuticals, Inc. 166.030 0.00

TABLE OF CONTENTS

Title Page

Policy Opportunities Portfolio ............................. 2Notes to Portfolio............................................... 7Report of Independent Registered

Public Accounting Firm .................................. 8Statement of Condition ..................................... 9The Portfolio ...................................................... A-1Objective and Securities Selection ..................... A-2Risk Factors....................................................... A-2Public Offering ................................................... A-4Retirement Accounts ......................................... A-8Fee Accounts .................................................... A-8Rights of Unitholders ......................................... A-9Portfolio Administration ...................................... A-12Taxation ............................................................. A-15Portfolio Operating Expenses............................. A-17Other Matters .................................................... A-18Additional Information ........................................ A-18

______________When Units of the Portfolio are no longer available thisprospectus may be used as a preliminary prospectus for afuture Portfolio. If this prospectus is used for future Portfoliosyou should note the following:

The information in this prospectus is not complete with respectto future Portfolio series and may be changed. No person maysell Units of future Portfolios until a registration statement isfiled with the Securities and Exchange Commission and iseffective. This prospectus is not an offer to sell Units and is notsoliciting an offer to buy Units in any state where the offer orsale is not permitted.

U-EMSPRO1841

PROSPECTUS

March 1, 2018

Policy OpportunitiesPortfolio 2018-1

Please retain this prospectus for future reference.

INVESCO